Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study.

IF 3.4 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Drugs & Aging Pub Date : 2023-10-01 Epub Date: 2023-08-08 DOI:10.1007/s40266-023-01057-x
Sandy Maumus-Robert, Ana Jarne-Munoz, Marie Tournier, Bernard Bégaud, Antoine Pariente
{"title":"Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study.","authors":"Sandy Maumus-Robert,&nbsp;Ana Jarne-Munoz,&nbsp;Marie Tournier,&nbsp;Bernard Bégaud,&nbsp;Antoine Pariente","doi":"10.1007/s40266-023-01057-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Benzodiazepines (including zolpidem and zopiclone) are often associated with higher-than-recommended intake and durations of use, especially in older adults. The objective of this study was to characterize trajectories of benzodiazepine use according to recommended patterns in older adults, and to assess predictors of the risk of developing each of these trajectories.</p><p><strong>Methods: </strong>Using the French Health Insurance database, we constituted a cohort of adults aged ≥ 65 years who initiated benzodiazepines in 2007 and were followed for up to 8 years. Concordance with benzodiazepine use guidelines was assessed on a quarterly basis according to a \"concordance-with-guideline score\" with values 1-5. Group-based trajectory modeling was then applied as implemented in the Proc Traj procedure in SAS to define guideline-concordant trajectories based on seven baseline patient-centered characteristics: sex, complementary health insurance coverage, treated alcohol and tobacco use disorder, polypharmacy, hospital stay, and registered chronic diseases.</p><p><strong>Results: </strong>Among 5080 new users (64.1% women, median age 74 years), six trajectories of benzodiazepine use were identified. Three, representing 70% of users, were concordant with guidelines, whereas three implied non-concordant benzodiazepine use for part or all of the benzodiazepine use follow-up. Polymedicated patients were more prone to develop chronic non-guideline-concordant initially guideline-concordant use, whereas those with a history of long-term disease and hospitalization were more likely to develop chronic non-guideline-concordant use. The number of prescribers during the first quarter, number of daily defined doses, use of loperamide, and use of psychostimulants were associated with a higher risk of developing an initial and persistent non-guideline-concordant use. Treatment initiation by a psychiatrist, initial use of World Health Organization (WHO) step-2 opioids and non-benzodiazepine anxiolytics or sedatives were associated with a higher risk of late non-guideline-concordant use.</p><p><strong>Conclusions: </strong>Concordance with guidelines varied over time during benzodiazepine use in older adults. A third of these adults will hypothetically follow one of the identified non-guideline-concordant trajectories, consisting of initial and/or late non-guideline concordance. This was associated with modifiable and nonmodifiable factors that clinicians should be aware of for tailoring the monitoring of patients.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-023-01057-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Benzodiazepines (including zolpidem and zopiclone) are often associated with higher-than-recommended intake and durations of use, especially in older adults. The objective of this study was to characterize trajectories of benzodiazepine use according to recommended patterns in older adults, and to assess predictors of the risk of developing each of these trajectories.

Methods: Using the French Health Insurance database, we constituted a cohort of adults aged ≥ 65 years who initiated benzodiazepines in 2007 and were followed for up to 8 years. Concordance with benzodiazepine use guidelines was assessed on a quarterly basis according to a "concordance-with-guideline score" with values 1-5. Group-based trajectory modeling was then applied as implemented in the Proc Traj procedure in SAS to define guideline-concordant trajectories based on seven baseline patient-centered characteristics: sex, complementary health insurance coverage, treated alcohol and tobacco use disorder, polypharmacy, hospital stay, and registered chronic diseases.

Results: Among 5080 new users (64.1% women, median age 74 years), six trajectories of benzodiazepine use were identified. Three, representing 70% of users, were concordant with guidelines, whereas three implied non-concordant benzodiazepine use for part or all of the benzodiazepine use follow-up. Polymedicated patients were more prone to develop chronic non-guideline-concordant initially guideline-concordant use, whereas those with a history of long-term disease and hospitalization were more likely to develop chronic non-guideline-concordant use. The number of prescribers during the first quarter, number of daily defined doses, use of loperamide, and use of psychostimulants were associated with a higher risk of developing an initial and persistent non-guideline-concordant use. Treatment initiation by a psychiatrist, initial use of World Health Organization (WHO) step-2 opioids and non-benzodiazepine anxiolytics or sedatives were associated with a higher risk of late non-guideline-concordant use.

Conclusions: Concordance with guidelines varied over time during benzodiazepine use in older adults. A third of these adults will hypothetically follow one of the identified non-guideline-concordant trajectories, consisting of initial and/or late non-guideline concordance. This was associated with modifiable and nonmodifiable factors that clinicians should be aware of for tailoring the monitoring of patients.

Abstract Image

从符合指南的角度看老年人苯二氮卓类药物的使用轨迹:一项全国性队列研究。
背景和目的:苯二氮卓类药物(包括唑吡坦和佐匹克隆)通常与高于建议摄入量和使用时间有关,尤其是在老年人中。本研究的目的是根据推荐的模式,描述老年人苯二氮卓类药物的使用轨迹,并评估每种轨迹的风险预测因素。方法:使用法国健康保险数据库,我们组成了一个年龄≥65岁的成年人队列,他们在2007年开始服用苯二氮卓类药物,并接受了长达8年的随访。根据值为1-5的“与指南一致性评分”,每季度评估一次与苯二氮卓类药物使用指南的一致性。然后,在SAS的Proc-Traj程序中应用基于群体的轨迹建模,以基于七个以患者为中心的基线特征来定义指南一致轨迹:性别、补充医疗保险、治疗过的烟酒使用障碍、多药治疗、住院和登记的慢性病。结果:在5080名新使用者中(64.1%为女性,中位年龄74岁),确定了六种苯二氮卓类药物的使用轨迹。三种(占70%的使用者)符合指南,而三种暗示部分或全部苯二氮卓类药物使用随访中苯二氮卓类药物的使用不一致。多药治疗的患者更容易出现慢性非指南一致性——最初是指南一致性使用,而那些有长期疾病史和住院史的患者更有可能出现慢性非准则一致性使用。第一季度的处方人数、每日规定剂量的数量、洛哌丁胺的使用和精神刺激剂的使用与最初和持续非指南一致使用的风险较高有关。由精神病学家开始治疗、首次使用世界卫生组织(世界卫生组织)第2阶段阿片类药物和非苯二氮卓类抗焦虑药或镇静剂与后期使用非指南药物的风险较高相关。结论:在老年人使用苯二氮卓类药物期间,与指南的一致性随着时间的推移而变化。其中三分之一的成年人将假设遵循已确定的非指南一致性轨迹之一,包括初始和/或晚期非指南一致。这与临床医生应该意识到的调整患者监测的可改变和不可改变因素有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drugs & Aging
Drugs & Aging 医学-老年医学
CiteScore
5.50
自引率
7.10%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信